newsfilter
← Latest News
Business Wire·

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

ZTS
  • The United States Department of Agriculture (USDA) has licensed Cytopoint Plus™ for the treatment of allergic dermatitis in dogs.
  • Cytopoint Plus is the first next-generation monoclonal antibody (mAb) licensed by the USDA to provide 75 days of allergic itch relief in a single injection.
  • The 75-day dosing interval represents the longest treatment duration of any licensed mAb for canine allergic dermatitis, reducing the frequency of required veterinary clinic visits.
  • Cytopoint Plus targets and neutralizes interleukin‑31 (IL‑31), the molecule responsible for transmitting itch signals in dogs.
  • Treatment with Cytopoint Plus begins relieving itch within 1 day and continues for 75 days per administration.
  • Zoetis Inc. expanded its canine dermatology portfolio with Cytopoint Plus, joining existing products Cytopoint (4–8 weeks relief) and Apoquel (fast-acting oral therapy).
  • Allergic dermatitis is the number one reason pet owners visit veterinarians, affecting roughly 1 in 4 dogs seeking veterinary help for itching.
  • Chronic allergic itch can cause persistent scratching, sleep disruption, behavior changes, anxiety, aggression, and touch sensitivity in dogs.
  • The extended treatment interval aims to improve compliance, minimize missed doses, reduce treatment-related stress for dogs, and simplify care for pet owners.
  • In clinical studies supporting approval, Cytopoint Plus demonstrated efficacy through Day 75 with a safety profile similar to Cytopoint, with reduced itch scores observed through Day 90 in some dogs.
  • Cytopoint Plus is administered subcutaneously by a veterinary health professional every 75 days as needed.
  • The product is designed to offer veterinarians and pet owners a personalized treatment option for managing canine allergic skin disease.